CAR001 / CaraVan Biologix - LARVOL DELTA

Chimeric Antigen Receptor-Glypican-3 T Cell Therapy CAR001 for Advanced Hepatocellular Carcinoma: a first-in-human, phase I Trial (IMMUNOLOGY 2026) - "A clinical trial in 10 GPC3⁺ patients was conducted via HAI or IV, with doses from 9E7 to 6E8 CAR-T cells. We identified high cell-surface-GPC3 binding sequence (EC₅₀ ratio vs GC33 = 0.023:0.203). CAR001 represents a promising advance in the treatment of advanced HCC with manageable safety. Patients with greater expansion tended to have deeper drops in DCP but not observed for AFP. Higher DP IFNg secretion inversely correlated with AFP reduction and DCP reduction."

First-in-human • Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3 • IFNG